{"a":[{"_":"Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B ","$":{"href":"/pharma/vertex-acquires-endocrine-disease-specialist-crinetics-10b","hreflang":"en"}}]}
PalsonifyatumelnantPositive
AI Analysis
Summary
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion, Vertex's largest deal ever, to gain access to Palsonify and atumelnant with combined peak sales potential exceeding $5 billion.
Outcome Details
Vertex acquires Crinetics for $10 billion
Importance:9/10
Sentiment:
0.70
M&Aacquisitionendocrine diseaseVertexCrinetics
Read the original article
Published by FierceBiotech on July 7, 2026 7:17 AM